These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3081248)

  • 1. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
    Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
    Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
    Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
    Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.
    Toledano M; Mathiot C; Michon J; Andreu G; Lando D; Brandely M; Fridman WH
    Cancer Immunol Immunother; 1989; 30(1):57-64. PubMed ID: 2513112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
    Han X; Itoh K; Balch CM; Pellis NR
    Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    Itoh K; Pellis NR; Balch CM
    Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
    Nii A; Sone S; Utsugi T; Yanagawa H; Ogura T
    Int J Cancer; 1988 Jan; 41(1):33-40. PubMed ID: 2826345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
    Itoh K; Tilden AB; Balch CM
    Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
    Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
    Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells.
    Matossian-Rogers A; Browne C; Turkish M; O'Byrne P; Festenstein H
    Br J Cancer; 1989 Apr; 59(4):573-7. PubMed ID: 2785398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral rIL2-based immunotherapy in B16 melanoma.
    Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
    J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.
    Guillou PJ; Sedman PC; Ramsden CW
    Cancer Immunol Immunother; 1989; 28(1):43-53. PubMed ID: 2462468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.